Cambridge, Massachusetts-based InVivo Therapeutics Holdings Corp. is making waves as a research and clinical-stage biotechnology and biomaterials company operating in the United States. The company is focused on the development and commercialization of biopolymer scaffolding devices designed to address the treatment of spinal cord injuries (SCI). In particular, it is currently in the process of creating a Neuro-Spinal Scaffold implant utilizing biocompatible and bioresorbable polymers. This cutting-edge implant involves Poly lactic-co-glycolic acid, a commonly-used resorbable suture polymer that provides biocompatible support for the device, and a positively-charged polymer called Poly-L-Lysine that enables cellular adhesion to the scaffold's surfaces. InVivo Therapeutics was incorporated in 2003, and is a company to keep an eye on in the rapidly-evolving field of biotechnology.